Hexarelin
Also known as: HEX, Examorelin
Hexarelin is one of the strongest GH-releasing peptides, also showing cardioprotective effects. It increases GH, IGF-1, and may protect against heart damage.
Research Status
Research compound
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Usually resolves within 1-2 hours. Minimise by rotating injection sites, allowing the solution to reach room temperature, and using proper injection technique. Apply ice if swelling persists.
Hexarelin is more selective for GH release than natural ghrelin and typically causes less appetite stimulation than GHRP-6. If appetite increases, manage with adequate protein intake and meal planning.
Transient vasodilation may occur within minutes of injection. Usually resolves within 10-15 minutes. Ensure adequate hydration.
May occur in the first few days of use. Ensure adequate hydration and sleep. Typically resolves with continued use as the body adapts.
Hexarelin causes minimal cortisol release compared to other GHRPs. Any elevation is typically transient and clinically insignificant in healthy individuals.
Continuous use leads to reduced GH response over 2-4 weeks. Implement cycling: 2 weeks on, 2 weeks off. This maintains efficacy and prevents receptor downregulation.
Results from repeated injections at the same site. Prevent by rotating injection sites systematically. Maintain at least 1 inch between injection points. Effects are usually reversible if site rotation is implemented.
Elevated IGF-1 from chronic GH stimulation may cause fluid retention and nerve compression. Monitor for wrist pain, tingling, or numbness. Implement cycling protocols and consider breaks if symptoms develop.
May occur as GH and IGF-1 increase, particularly in the first 1-2 weeks. Usually self-resolving. Ensure adequate hydration and electrolyte intake.
GH is counter-regulatory and typically raises blood glucose; however, in sensitive individuals or with concurrent insulin use, transient hypoglycaemia is possible. Monitor blood glucose if diabetic or using insulin. Inject in a fasted state but have a carbohydrate source available.
True IgE-mediated allergies to hexarelin are extremely rare but possible. Symptoms include rash, hives, difficulty breathing, or throat swelling. Seek immediate medical attention if anaphylaxis occurs. Discontinue use if allergic symptoms develop.
Hexarelin may cause transient increases in heart rate or blood pressure. Individuals with pre-existing cardiac arrhythmias or uncontrolled hypertension should consult a cardiologist before use. Seek medical evaluation if chest pain, severe palpitations, or syncope occur.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 100 mcg |
| Frequency | 2x daily |
| Timing | Morning and evening (fasted) |
| Route | Subcutaneous |
Cycle 2 weeks on, 2 weeks off to prevent desensitization.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 1323.5 g/mol |
| Half-life | 30-40 minutes (endogenous GH secretion can persist 2-4 hours post-injection) |
| Sequence | His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 |
Hexarelin is a synthetic growth hormone-releasing peptide (GHRP) that acts as a ghrelin receptor agonist, binding to growth hormone secretagogue receptors (GHS-R1a) on pituitary somatotroph cells and hypothalamic neurons. This stimulates the release of endogenous growth hormone (GH) and increases circulating insulin-like growth factor-1 (IGF-1). Beyond GH secretion, hexarelin demonstrates cardioprotective effects through anti-inflammatory and anti-apoptotic mechanisms in cardiac tissue, making it unique among GHRPs.
GHS-R1a Receptor Activation
Hexarelin binds to growth hormone secretagogue receptors on pituitary somatotrophs and hypothalamic neurons, triggering GH release through both direct pituitary stimulation and GHRH-mediated pathways. This is the primary mechanism driving increased GH and IGF-1 secretion.
Cardioprotective Signalling
Hexarelin activates GHS-R1a on cardiac myocytes and endothelial cells, triggering anti-inflammatory cytokine release, reduced oxidative stress, and inhibition of apoptotic pathways. This protects against ischaemic injury and may improve cardiac function in models of heart failure.
IGF-1 Axis Upregulation
Increased GH secretion stimulates hepatic and peripheral IGF-1 production, which mediates many anabolic and metabolic effects including protein synthesis, lipolysis, and bone turnover.
- Hexarelin is one of the most potent GHRPs, producing GH release comparable to or exceeding that of GHRP-6 and GHRP-2
- Unlike natural ghrelin, hexarelin does not significantly stimulate appetite or cortisol release, making it more selective for GH secretion
- Cardioprotective effects are mediated through GHS-R1a signalling independent of GH secretion, suggesting direct cardiac benefits
- Desensitisation (tachyphylaxis) occurs with continuous use; cycling protocols (2 weeks on, 2 weeks off) are recommended to maintain efficacy
- Hexarelin has been investigated in clinical trials for heart failure and ischaemic cardiomyopathy due to its dual GH-releasing and cardioprotective properties
Track your Hexarelin research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Hexarelin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.